Skip to main content
See every side of every news story
Published • loading... • Updated

Pfizer Will No Longer Sell Hormone Replacement Therapy in Canada

Pfizer said the decision follows an internal review and is not tied to safety concerns, while tablet stocks may last until mid-2027.

  • On Thursday, Pfizer Canada confirmed it will stop selling the hormone replacement therapy Premarin following an internal review, stating the decision is not related to safety, efficacy, or quality concerns.
  • The vaginal cream has been in shortage since June, while existing inventories of 0.3 mg, 0.625 mg, and 1.25 mg strength tablets are expected to last until about mid-2027.
  • Premarin Intravenous, used for hospital treatment of abnormal uterine bleeding, remains unaffected, and Pfizer Canada advises patients to consult healthcare providers before changing hormone replacement treatments.
  • This discontinuation exacerbates existing supply constraints in Canada, where Health Canada reported intermittent shortages of estradiol transdermal patches by Bayer and Sandoz expected to continue until early 2027.
  • While the decision applies only to Canada, Pfizer continues selling Premarin products in the United States, Australia, New Zealand, and Singapore, declining to comment on supply situations in other markets.
Insights by Ground AI

8 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 43% of the sources are Center, 43% of the sources lean Right
43% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WTVB broke the news on Thursday, November 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal